Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Knee Pain Health Center

Font Size

FDA Nixes Vioxx-Like Pain Drug

Drug, Called Arcoxia, Will Continue to Be Sold Overseas, Says Drug's Maker
WebMD Health News
Reviewed by Louise Chang, MD

April 27, 2007 -- The drug company Merck today announced that the FDA has rejected Merck's application to market Arcoxia, a new osteoarthritis drug.

Arcoxia is similar to Vioxx, a drug removed from the U.S. market in 2004 because of an increased heart attack and stroke risk.

The decision follows the advice of an FDA advisory panel, which voted 20 to 1 earlier this month to reject Arcoxia.

Arcoxia is in the class of nonsteroidal anti-inflammatory drugs (NSAIDs) known as Cox-2 inhibitors, which includes Vioxx and Bextra -- both removed from U.S. pharmacies -- as well as Celebrex, which is still on the market. Cox-2 drugs have a lower risk for stomach ulcers and gastrointestinal bleeding than other NSAIDs such as aspirin and ibuprofen.

Arcoxia is sold in 63 countries. The drug represented Merck's first attempt to return to the once-lucrative Cox-2 pain drug market in the U.S.

The company had hoped to convince experts that the drug was a better pain drug than related drugs -- and also that it was safer.

In a news release issued today, Merck says the FDA's letter indicated that Merck "would need to provide additional data in support of the benefit-to-risk profile for the proposed doses of Arcoxia in order to gain approval."

"We are disappointed with today's decision," says Peter S. Kim, PhD, president of Merck Research Laboratories, in Merck's news release.

Kim says Merck strongly believes that "new medicines are needed for patients whose osteoarthritis pain is inadequately managed with currently available therapies."

Kim also states that "there is more long-term safety data from controlled clinical trials, in terms of patient-years on treatment, for Arcoxia than for any other NSAID, including traditional NSAIDs and Cox-2 selective inhibitors."

Merck says it will continue to market Arcoxia outside the U.S.

Today on WebMD

knee exercise
If you're living with knee pain, try these.
knee in brace
Everything you wanted to know about it.
nurse helping woman on crutches
When it comes to knee pain.
man with knee pain
Read this first.
man biting a bullet
6 Ways To Ruin Your Knees
Keep Joints Healthy
Knee exercises